Sofosbuvir, velpatasvir and voxilaprevir

(Vosevi®)

Vosevi®

Drug updated on 11/14/2023

Dosage FormTablet (oral: 400 mg sofosbuvir, 100 mg velpatasvir, and 100 mg voxilaprevir)
Drug ClassMultiple
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult patients with chronic HCV infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have (1, 2.2, 14) genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor.
  • For the treatment of adult patients with genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor.